A Study of Bimatoprost 0.01% in the Clinical Setting

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Diagnosis of primary open-angle glaucoma or ocular hypertension

• Determined by the treating physician to require treatment with bimatoprost 0.01%.

Exclusion Criteria:

• Previous use of Lumigan® 0.01%